Tolerability and Safety Profile of 12-to 28-Week Treatment with Interferon Beta-1b 250 and 500 μg QOD in Patients with Relapsing-Remitting Multiple Sclerosis : A Multicenter, Randomized, Double-Blind, Parallel-Group Pilot StudyHURWITZ, Barrie J; JEFFERY, Douglas; MIKOL, Daniel et al.Clinical therapeutics. 2008, Vol 30, Num 6, pp 1102-1112, issn 0149-2918, 11 p.Article

Interferon-β-1b: A Review of its Use in Multiple SclerosisPLOSKER, Greg L.CNS drugs. 2011, Vol 25, Num 1, pp 67-88, issn 1172-7047, 22 p.Article

Interferon-β-1b : In Newly Emerging Multiple SclerosisMCKEAGE, Kate.CNS drugs. 2008, Vol 22, Num 9, pp 787-792, issn 1172-7047, 6 p.Article

Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with IFN-βKAROW, Anne-Christine; BRAUN, Jürgen; MARX, Peter et al.Journal of neurology. 2002, Vol 249, Num 8, pp 1121-1122, issn 0340-5354, 2 p.Article

Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b. CommentaryNARAYANAN, Sridar; DE STEFANO, Nicola; MATTHEWS, P. M et al.Journal of neurology. 2001, Vol 248, Num 11, pp 979-987, issn 0340-5354Article

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple SclerosisMARZINIAK, Martin; MEUTH, Sven.Advances in therapy. 2014, Vol 31, Num 9, pp 915-931, issn 0741-238X, 17 p.Article

Pharmacoeconomic Considerations in the Treatment of Multiple SclerosisSHARAC, Jessica; MCCRONE, Paul; SABES-FIGUERA, Ramon et al.Drugs (Basel). 2010, Vol 70, Num 13, pp 1677-1691, issn 0012-6667, 15 p.Article

Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1bMARKOVIC-PLESE, S; BIELEKOVA, B; KADOM, N et al.Neurology. 2003, Vol 60, Num 11, pp 1849-1851, issn 0028-3878, 3 p.Article

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology. 2001, Vol 57, Num 12, pp S3-S9, issn 0028-3878, SUP5Article

Liver and thyroid function and autoimmunity during interferon-β1b treatment for MSDURELLI, L; FERRERO, B; OGGERO, A et al.Neurology. 2001, Vol 57, Num 8, pp 1363-1370, issn 0028-3878Article

The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MSBREX, P. A; MOLYNEUX, P. D; POLMAN, C. H et al.Neurology. 2001, Vol 57, Num 12, pp 2185-2190, issn 0028-3878Article

Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple SclerosisTHOMPSON, Joel P; ABDOLAHI, Amir; NOYES, Katia et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 6, pp 455-469, issn 1170-7690, 15 p.Article

Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplementTAMURA, S; WARABI, Y; MATSUBARA, S et al.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 6, pp 724-725, issn 0269-4727, 2 p.Article

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1bSORMANI, M. P; BRUZZI, P; BECKMANN, K et al.Neurology. 2003, Vol 60, Num 9, pp 1462-1466, issn 0028-3878, 5 p.Article

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1 a (Rebif) treatment trial. CommentaryLIN, X; TENCH, C. R; TURNER, B et al.Journal of neurology, neurosurgery and psychiatry. 2003, Vol 74, Num 8, pp 1014-1015, issn 0022-3050, 7 p.Article

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNβ-1bRAO, A. B; RICHERT, N; HOWARD, T et al.Neurology. 2002, Vol 59, Num 5, pp 688-694, issn 0028-3878Article

Statins as immunomodulators: Comparison with interferon-β1b in MSNEUHAUS, O; STRASSER-FUCHS, S; FAZEKAS, F et al.Neurology. 2002, Vol 59, Num 7, pp 990-997, issn 0028-3878Article

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction studyBARBERO, Pierangelo; VERDUN, Elisabetta; BERGUI, Mauro et al.Journal of the neurological sciences. 2004, Vol 222, Num 1-2, pp 13-19, issn 0022-510X, 7 p.Article

Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort studyPOZZILLI, Carlo; SCHWEIKERT, Bernd; ECARI, Ugo et al.Journal of the neurological sciences. 2011, Vol 307, Num 1-2, pp 120-126, issn 0022-510X, 7 p.Article

Genomics and proteomics : role in the management of multiple sclerosisKAPPOS, Ludwig; ACHTNICHTS, Lutz; DAHLKE, Frank et al.Journal of neurology. Supplement. 2005, Vol 252, Num 3, pp III21-III27, issn 0939-1517Article

Induction of TNFf-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activityLASKE, C; OSCHMANN, P; TRAUPE, H et al.Acta neurologica scandinavica. 2001, Vol 103, Num 2, pp 105-113, issn 0001-6314Article

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?DURELLI, Luca; OGGERO, Alessandra; VERDUN, Elisabetta et al.Journal of the neurological sciences. 2000, Vol 178, Num 1, pp 37-41, issn 0022-510XArticle

Emotional state of patients with relapsing-remitting MS treated with interferon beta-1bBORRAS, C; RIO, J; PORCEL, J et al.Neurology. 1999, Vol 52, Num 8, pp 1636-1639, issn 0028-3878Article

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administrationKHAN, O. A; XIA, Q; BEVER, C. T et al.Neurology. 1996, Vol 46, Num 6, pp 1639-1643, issn 0028-3878Article

Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosisARNASON, Barry G. W.Journal of neurology. Supplement. 2005, Vol 252, Num 3, pp III28-III33, issn 0939-1517Article